Sight Sciences Inc (SGHT) Peer Comparison

$8.47

$0.10 (1.19%)

As on 27-Aug-2026 15:35EDT

Market cap

$455 Mln

Revenue (TTM)

$83 Mln

P/E Ratio

--

P/B Ratio

8.5

Div. Yield

0 %

Edit

	Sight Sciences Inc (SGHT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	455	12,753	10,906	9,762	10,222
Revenue ($ Mln)	83	1,505	613	2,589	785
Net Profit ($ Mln)	-29.76	160.59	-188.05	222.40	41.54
Net Margin (%)	-35.69	10.67	-30.68	8.59	5.29
RoE (%)	-50.94	10.86	-28.10	3.04	1.97
Price to Earnings	--	79.35	--	44.47	251.57
Price-To-Book	8.48	8.41	16.38	1.26	4.84

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Sight Sciences Inc (SGHT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	83.38	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	10.04	483.98	127.96	1,245.50	384.30
Gross Profit	66.67	942.44	393.22	1,343.60	347.62
Operating Expenses	101.21	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	-27.88	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-29.79	203.83	-192.83	350.40	52.15
Provision for Tax	-0.03	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	-29.76	160.59	-188.05	222.40	41.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Sight Sciences Inc (SGHT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	52.89	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	31.48	210.18	135.71	2,116.80	705.49
Current Liabilities	20.50	233.78	102.33	961.30	132.66
Total Liabilities	115.30	1,826.52	893.49	10,576.50	2,949.70

Assets ($ Mln)

	Sight Sciences Inc (SGHT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	3.43	630.60	404.74	7,231.50	1,749.63
Current Assets	101.44	1,344.12	515.78	3,020.50	1,200.55
Total Assets	115.30	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	41.97	212.71	102.84	1,203.70	690.94
Net Current Assets	80.94	1,110.35	413.45	2,059.20	1,067.90

Cashflow ($ Mln)

	Sight Sciences Inc (SGHT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	-29.69	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	-0.22	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	1.79	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Sight Sciences Inc (SGHT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	-33.04	11.76	-22.53	8.98	1.79
ROE (%)	-50.94	10.86	-28.10	3.04	1.97
ROA (%)	-22.95	7.95	-18.00	2.02	1.36
EBIT Margin (%)	-31.37	13.63	-30.58	-5.99	9.87
Net Margin (%)	-35.69	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Sight Sciences Inc (SGHT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	9.27	17.55	41.55	1.37	16.49
EBIT Growth (%)	40.37	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	39.28	8.72	-102.66	-30.32	400.42
EPS Growth (%)	41.99	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	-28.17	17.33	-12.65	2.19	2.16

Valuation Ratios

	Sight Sciences Inc (SGHT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	-10.95	68.93	-34.59	--	189.42
Price / Book Value	6.58	8.58	9.90	--	4.40
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-11.28	53.25	-43.50	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Sight Sciences Inc (SGHT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.58	0.00	0.00	0.11	0.26
Short term debt to equity ratio	0.20	0.01	0.00	0.06	0.01
Current Ratio	4.95	5.75	5.04	3.14	9.05
Quick Ratio	4.67	3.86	4.46	2.33	7.64
Interest Coverage	-4.78	157.91	-38.31	8.18	3.36

Operating Efficiency Ratios

	Sight Sciences Inc (SGHT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	13.66	12.65	22.67	17.06	20.09
Asset Turnover	0.64	0.74	0.59	0.24	0.26
Receivable days	48.47	46.54	60.95	65.39	72.41
Inventory Days	240.59	331.92	193.84	221.09	146.53
Payable days	51.80	26.16	60.19	37.02	29.05
Cash Conversion Cycle	237.25	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly